Evidence map›Paper›PMID 25413141›Full record

ArticleTransfusion2015

Enhanced detection of viral diversity using partial and near full-length genomes of human immunodeficiency virus Type 1 provirus deep sequencing data from recently infected donors at four blood centers in Brazil.

Rodrigo Pessôa, Jaqueline Tomoko Watanabe, Paula Calabria, Cecilia Salete Alencar, Paula Loureiro, Maria Esther Lopes, Anna Barbara Proetti, Alvina Clara Félix, Ester C Sabino, Michael P Busch and 2 more

Open access · greenAbstract read
In one paragraph

Article in Transfusion, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Rodrigo PessôaDepartment of Virology, São Paulo Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil.
Jaqueline Tomoko WatanabeDepartment of Virology, São Paulo Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil.
Paula CalabriaDepartment of Virology, São Paulo Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil.
Cecilia Salete AlencarClinical Laboratory, Department of Pathology, LIM 03, Hospital das Clínicas (HC), School of Medicine, University of São Paulo, São Paulo, Brazil.
Paula LoureiroPernambuco State Center of Hematology and Hemotherapy-HEMOPE, Recife, Pernambuco, Brazil.
Maria Esther LopesHemorio, Rio de Janeiro, Brazil.
Anna Barbara ProettiMinas Gerais State Center of Hematology and Hemotherapy-HEMOMINAS, Belo Horizonte, Minas Gerais, Brazil.
Alvina Clara FélixDepartment of Virology, São Paulo Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil.
Ester C SabinoDepartment of Infectious Disease/Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil.
Michael P BuschBlood Systems Research Institute, San Francisco, California.
Sabri S SanabaniClinical Laboratory, Department of Pathology, LIM 03, Hospital das Clínicas (HC), School of Medicine, University of São Paulo, São Paulo, Brazil.
International Component of the NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)
Universidade de São Paulo · BRHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRBlood Systems Research Institute · USFundação Centro de Hematologia e Hemoterapia de Minas Gerais · BRFundação Hemopa · BRHemorio · BR

Funding

NHLBI NIH HHS HHSN268200417175CNHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100007I
6 · The paper itself

Abstract

backgroundHere, we report application of high-throughput near full-length genome (NFLG) and partial human immunodeficiency virus Type 1 (HIV-1) proviral genome deep sequencing to characterize HIV in recently infected blood donors at four major blood centers in Brazil. STUDY DESIGN AND

methodsFrom 2007 to 2011, a total of 341 HIV+ blood donors from four blood centers were recruited to participate in a case-control study to identify HIV risk factors and motivations to donate. Forty-seven (17 from São Paulo, eight from Minas Gerais, 11 from Pernambuco, and 11 from Rio de Janeiro) were classified as recently infected based on testing by less-sensitive enzyme immunoassays. Five overlapping amplicons spanning the HIV genome were polymerase chain reaction amplified from peripheral blood mononuclear cells. The amplicons were molecularly barcoded, pooled, and sequenced by a paired-end protocol (Illumina).

resultsOf the 47 recently infected donor samples studied, 39 (82.9%) NFLGs and six (12.7%) partial fragments were de novo assembled into contiguous sequences and successfully subtyped. Subtype B was the only nonrecombinant virus identified in this study and accounted for 62.2% (28/45) of samples. The remaining 37.8% (17/45) of samples showed various patterns of subtype discordance in different regions of HIV-1 genomes, indicating two to four circulating recombinant subtypes derived from Clades B, F, and C. Fourteen samples (31.1%) from this study harbored drug resistance mutations, indicating higher rate of drug resistance among Brazilian blood donors.

conclusionOur findings revealed a high proportion of HIV-1 recombinants among recently infected blood donors in Brazil, which has implications for future blood screening, diagnosis, therapy, and vaccine development.

Indexed as

Blood DonorsBrazilGenome, ViralHigh-Throughput Nucleotide SequencingHIV-1HumansImmunoenzyme TechniquesMolecular Sequence Data

Identifiers

PMID25413141
PMCPMC4428985
OpenAlexW1909501981

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.